1-3 of 3
Manjula Reddy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma

Clinical Trials & Observations
Jesús San-Miguel, Joan Bladé, Ofer Shpilberg, Sebastian Grosicki, Frédéric Maloisel, Chang-Ki Min, Marta Polo Zarzuela, Tadeusz Robak, Sripada V. S. S. Prasad, Yeow Tee Goh, Jacob Laubach, Andrew Spencer, María-Victoria Mateos, Antonio Palumbo, Tom Puchalski, Manjula Reddy, Clarissa Uhlar, Xiang Qin, Helgi van de Velde, Hong Xie, Robert Z. Orlowski
Journal: Blood
Blood (2014) 123 (26): 4136–4142.
https://doi.org/10.1182/blood-2013-12-546374
Published: 2014
Journal Articles

Population Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody, Siltuximab (CNTO 328), in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Lanyi Xie, PhD, Lilian Y Li, PhD, Razelle Kurzrock, MD, Frits van Rhee, MD, PhD, Xiang Qin, MS, Manjula Reddy, MS, Ming Qi, MD, PhD, Hugh M Davis, PhD, Honghui Zhou, PhD, Thomas A Puchalski, PharmD
Journal: Blood
Blood (2012) 120 (21): 1365.
https://doi.org/10.1182/blood.V120.21.1365.1365
Published: 2012
Journal Articles

CNTO328 (Anti-IL-6 mAb) Treatment Is Associated with An Increase in Hemoglobin (Hb) and Decrease in Hepcidin Levels in Renal Cell Carcinoma (RCC).

Martin Schipperus, Britte Rijnbeek, Manjula Reddy, Xiang Qin, Mark J. Cornfeld
Journal: Blood
Blood (2009) 114 (22): 4045.
https://doi.org/10.1182/blood.V114.22.4045.4045
Published: 2009